A carregar...
Facial erythema after the treatment of dupilumab in SLE patient
BACKGROUND: Dupilumab is a receptor antagonist binding to the alpha subunit of the interleukin-4 receptor. Through binding to it, dupilumab inhibits signaling of both IL-4 and IL-13, the representative Th2 biomarkers. Recently, in addition to the treatment effects for atopic dermatitis (AD), there i...
Na minha lista:
| Publicado no: | Allergy Asthma Clin Immunol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7491356/ https://ncbi.nlm.nih.gov/pubmed/32944024 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13223-020-00458-6 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|